Amylyx Pharmaceuticals (AMLX) Citi's Biopharma Back to School Conference summary

Clinical development updates

• AIDA (avexitide), a GLP-1 receptor antagonist, is in Phase III for post-bariatric hypoglycemia (PBH), with recruitment completion expected by year-end and top-line data in the first half of 2026.

• Five prior positive studies led to FDA breakthrough therapy designation; the current trial is expected to be pivotal for registration.

• The LUCIDITY study targets reduction in Level II and III hypoglycemic events, with secondary endpoints including quality of life and healthcare utilization.

• Patient recruitment is progressing well, driven by high unmet need and strong interest from endocrinologists.

• Structured patient interviews are included to assess real-world impact and patient experience.

Market opportunity and patient population

• PBH affects about 160,000 people in the US, primarily as a rare but persistent complication after bariatric surgery.

• The PBH population is expected to grow with continued bariatric procedures, and the condition is more common in women in their 40s.

• PBH patients experience frequent, unpredictable hypoglycemic events, leading to significant lifestyle limitations and risk.

• Current treatments are limited to medical nutrition therapy and off-label hormonal agents, both with limited efficacy and tolerability.

• There are no approved therapies for PBH, positioning avexitide as a potential first-in-class treatment.

Commercial strategy and payer engagement

• The rare disease model is being leveraged, with targeted education for physicians and payers about the severity and burden of PBH.

• Any reduction in significant hypoglycemic events is considered meaningful by physicians and payers.

• Commercial launch plans focus on centers with high patient concentrations and ongoing education to improve diagnosis and awareness.

• Recent rare endocrine launches support premium pricing and access in high unmet need areas.

• PBH is increasingly recognized in medical education and board exams, supporting future market growth.